<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>umbrella review methodology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/umbrella-review-methodology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:59:40 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>umbrella review methodology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Statins Lower HCC Risk in MASLD, T2DM</title>
		<link>https://bioengineer.org/statins-lower-hcc-risk-in-masld-t2dm/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 May 2025 22:59:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[hepatocellular carcinoma prevention]]></category>
		<category><![CDATA[metabolic dysfunction-associated steatotic liver disease (MASLD)]]></category>
		<category><![CDATA[statin therapy benefits]]></category>
		<category><![CDATA[type 2 diabetes complications]]></category>
		<category><![CDATA[umbrella review methodology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/statins-lower-hcc-risk-in-masld-t2dm/</guid>

					<description><![CDATA[In a landmark umbrella review published in BMC Cancer, researchers have delved deeply into the complex relationship between statin use and the risk of developing hepatocellular carcinoma (HCC) in individuals afflicted with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). This comprehensive analysis synthesizes evidence from multiple meta-analyses and systematic reviews [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">245211</post-id>	</item>
	</channel>
</rss>
